Search
Selected Filter
Filter Results
Displaying 101–110 of 317 research results
-
Mar 24, 2021
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
The company is planning two Phase 2/3 clinical trials for the treatment
-
Mar 16, 2021
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
More than 8,000 people have applied for genetic testing through the Foundation’s program
-
Feb 17, 2021
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
His latest Foundation grant is helping move the drug toward a clinical trial
-
Feb 11, 2021
Are You on the Clinical Trial Radar Screen?
Therapy developers use the My Retina Tracker Registry to recruit for human studies of emerging therapies
-
Feb 2, 2021
Very-Long-Chain Polyunsaturated Fatty Acids Improve Vision in Mice with a Form of Stargardt Disease
Researchers believe the VLC-PUFAs may benefit people with autosomal dominant Stargardt disease, AMD, and possibly other retinal degenerations
-
Jan 28, 2021
The company plans to enroll additional patients as young as four years old
-
Jan 26, 2021
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Company will seek marketing approval for the emerging therapy
-
Jan 13, 2021
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Company also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
-
Jan 7, 2021
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
In a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
Dec 7, 2020
Penn Vet’s William Beltran Elected to the National Academy of Medicine
The veterinary researcher’s canine studies are advancing promising retinal therapies toward clinical trials